A forum for researchers, students and applicants in the field of cyclodextrin technology
If approved, ZULRESSO would be the first medicine specifically indicated for the treatment of postpartum depression (PPD) Sage Therapeutics (NASDAQ:
Cyclodextrins (CDs) have become a very common building-block for the design of new smart materials of different nature. This is
Methylated α-CD (MeACD) loaded with exogenous lipids was used to replace the endogenous phospholipids and sphingolipids from cell plasma membrane
Polylactic acid (PLLA) was internally blended with zinc oxide nanoparticles and chitosan and carboxyethyl BCD (CEBCD) layers were deposited by
If approved, ZULRESSO would be the first medicine specifically indicated for the treatment of postpartum depression (PPD) Sage Therapeutics (NASDAQ:
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, announced positive
Mallinckrodt Pharmaceuticals recently revealed findings of their completed registration trial for VTS-270 (Hydroxypropyl Betadex- HPBCD), a development product to treat
Federal Research Institute of Pediatric Hematology, Oncology and Immunology is about to launch a clinical study at Dmitry Rogachev National
A recently published patent application of Cell and Molecular Tissue Engineering LLC (WO2017180708) discloses a method of lowering the concentrations of
A recent paper in Drug Design, Development and Therapy gives an overview on the new strategies to combat antifungal drug
Cyclodextrins (CDs) have become a very common building-block for the design of new smart materials of different nature. This is
CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with
Novel biodegradable nanofilter membrane (BCD-PDA@PLA) was developed by electrospinning poly(L-lactic acid) (PLA) nanofibers as the scaffold, which were then surface
